An observational study in Familial Pancreatic Cancer, BRCA1 Mutation and BRCA2 Mutation, sponsored by Associazione Italiana per lo Studio del Pancreas. Recruiting at 4 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-13.
Sponsored by Associazione Italiana per lo Studio del Pancreas · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy — 9 open to participants now, 9 under way, none of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · Italy.
Among the 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy, this one is the only one that started in 2019, is one of 7 observational ones, and was the 1st registered.
147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 61 are open to participants now.
Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →9 of the 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy are open now. Recruiting first, the newest first:
Vividion Therapeutics, Inc. · Sites in Italy, United States, Argentina and 19 more countries
Ages 18+
San Raffaele University · Sites in Italy
Ages 18+ · Healthy volunteers
San Raffaele University · Sites in Italy, United States
Ages 18+
San Raffaele University · Sites in Italy
Ages 18+ · Healthy volunteers
UNICANCER · Sites in Italy, Croatia, Czechia and 6 more countries
Ages 35–80
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2019.
This study's planned enrollment of 1,000 is above the median of 400 across 66 observational studies indexed under Colorectal Neoplasms, Hereditary Nonpolyposis.
Median enrollment 140 across the 3 interventional studies, 300 across the 7 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 8 most frequent:
Associazione Italiana per lo Studio del Pancreas is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Associazione Italiana per lo Studio del Pancreas has 1 study filed under Colorectal Neoplasms, Hereditary Nonpolyposis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
Pancreatic cancer is a devastating disease with a dismal prognosis. One of the ways to improve survival might be early detection.
Within years, many predisposing diseases or genetic conditions have been identified, thus screening/surveillance have been established worldwide.
A registry of subjects at risk of pancreatic cancer will has been built up to investigate the possibility of diagnosis pancreatic cancer, or one if its predisposing lesions.
Inclusion criteria will be adopted as "enrollment criteria". According to this, individuals > 18 years old will be enrolled; their familiar history and/or genetic predisposition will be collected, as well as current or previous medical records/medications data. Thereafter, according to specific age-based criteria, those individuals initially enrolled will be will be considered for a "surveillance protocol" ("interventional follow-up criteria") and they will be submitted to Cholangio-Wirsung Magnetic Resonance or Pancreatic Endoultrasonography according to the pancreatologist's prescription at each participating center.
Individuals suffering from the following conditions will be enrolled:
familial pancreatic cancer; Peutz-Jeghers syndrome; a known BRCA-2, BRCA-1, PALB2, or p16 mutation with at least one first- or second-degree relative suffering from pancreatic cancer; hereditary pancreatitis; FAMMM syndrome; Lynch syndrome with at least one first- or second-degree relative suffering from pancreatic cancer.
Subjects at high-risk of pancreatic cancer will be enrolled and a surveillance examination will be performed according to inclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria to join the "radiologic follow-up":
Exclusion Criteria:
Radiation: MRCP · Procedure: Endoultrasonography
Radiation: MRCP · Procedure: Endoultrasonography
Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC
Radiation: MRCP · Procedure: Endoultrasonography
Radiation: MRCP · Procedure: Endoultrasonography
Radiation: MRCP · Procedure: Endoultrasonography
Radiation: MRCP · Procedure: Endoultrasonography
Subjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription
Subjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription
This clinical study will assess the diagnostic yield of a clinical surveillance program for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals
Number of malignant and pre-malignant lesions diagnosed over time
Time frame: 25 years
This study will investigate possible risk factors for the incidence or the progression of for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals
Identification of risk factors for malignant or pre-malignant lesions diagnosis
Time frame: 25 years
Plan to share: No
Started Aug 2019 (actual). Primary completion is estimated for Aug 2044, 300 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Colorectal Neoplasms, Hereditary Nonpolyposis →
Associazione Italiana per lo Studio del Pancreas